In Radenci, Slovenia, a jubilee annual scientific and expert meeting with international attendance, endorsed by the Slovenian Society of Cardiology - the 30th Annual Meeting (30. Radenski dnevi) took place from 10 to 12 May 2012.
At the meeting, the leading experts in cardiovascular medicine discussed how to most efficiently transfer the knowledge and findings obtained in scientific research to the daily clinical practice.
As part of the event Krka organised an international satellite symposium titled 'Reaching the targets. Reducing the risk.' on 10 May 2012. The contents of the symposium addressed the area of cardiovascular disease from the point of its two main risk factors – hyperlipidemia and hypertension. The symposium chairman Prof. Zlatko Fras, pointed out the importance of an integrated approach in the management of patients at risk for the development or exacerbation of cardiovascular disease. The first speaker, Assist. Prof. Michal Vrablík from the Czech Republic presented in his lecture how important it is to effectively treat patients with elevated blood lipid levels and to achieve the target levels by long-term treatment with adequate doses of newer statins as is rosuvastatin. Prim. Dr. Borut Kolšek emphasised the importance of reaching the target levels in the treatment of high blood pressure and pointed out the significant advantages of fixed-dose combination therapy, primarily of perindopril and amlodipine. In the closing part of the symposium, Krka's product manager Sanja Brus stressed that a major Krka’s mission is the continuous development of modern cardiovascular medicines, and among them underlined rosuvastatin and the fixed-dose combination of perindopril and amlodipine.
Krka’s satellite symposium was attended by more than 120 participants from Slovenia, Poland, and Czech Republic. After presentations, the participants started a vivid discussion about adequate therapies in everyday clinical practice that ensure best control of the risk factors of cardiovascular diseases.
